Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Illumina

Evaluate

Thumbnail
March 15, 2023

Illumina investors give long reads short shrift

December 06, 2022

Illumina loses its grip

The sequencing giant’s acquisition of Grail is heading for the rocks.

Article image
Vantage logo
October 14, 2022

Medtech bleeds corporate venture cash

Overall venture investment in the sector remains steady, but the big strategics back off.

Article image
Vantage logo
September 30, 2022

Investors shrug off Illumina’s $200 genome

Article image
Vantage logo
September 29, 2022

Ember burns bright for Angle

A clinical hit could allow the group’s liquid biopsy to expand from breast cancer to ovarian.

Article image
Vantage logo
September 12, 2022

Esmo 2022 – Exact trails Grail on sensitivity

Article image
Vantage logo
September 08, 2022

Esmo 2022 – Galleri’s real-world exhibition disappoints

Grail finds the path for its liquid biopsy less clear than it might have hoped.

Article image
Vantage logo
September 06, 2022

The outlook darkens for Illumina

Article image
Vantage logo
September 02, 2022

Illumina wins in the US but fears a loss in Europe

Article image
Vantage logo
August 05, 2022

Delfi aims for a cheaper liquid biopsy

With a fresh $225m in the bank, Delfi works towards a cut-price, next-generation lung cancer screen.

Article image
Vantage logo
May 25, 2022

A new kind of liquid biopsy

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 17, 2023

PD(L)anner – February 2023

February 09, 2023

Biopharma and Medtech Review 2022

View more...

Editor's Picks

Vantage logo
March 13, 2023

Silicon Valley Bank: biopharma’s latest crisis

Vantage logo
March 13, 2023

Pfizer rescues biotech

Vantage logo
February 28, 2023

Why Pfizer (and others) will be interested in Seagen

Vantage logo
March 04, 2023

ACC 2023 – Esperion’s outcomes win looks lacklustre

Vantage logo
March 06, 2023

T-cell receptor behemoths consolidate? Not quite

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up